Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 2,450,000 shares, an increase of 9.4% from the March 15th total of 2,240,000 shares. Approximately 6.2% of the shares of the company are sold short. Based on an average trading volume of 179,700 shares, the short-interest ratio is presently 13.6 days.

Aura Biosciences Price Performance

NASDAQ:AURA opened at $7.26 on Wednesday. The firm’s fifty day moving average price is $8.17 and its 200 day moving average price is $8.32. Aura Biosciences has a 1-year low of $5.99 and a 1-year high of $13.50. The firm has a market cap of $359.37 million, a price-to-earnings ratio of -3.78 and a beta of 0.36.

Insider Transactions at Aura Biosciences

In other news, CFO Julie B. Feder sold 6,609 shares of the firm’s stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total transaction of $50,492.76. Following the transaction, the chief financial officer now directly owns 62,991 shares in the company, valued at $481,251.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Los Pinos Elisabet De sold 15,853 shares of Aura Biosciences stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total value of $121,116.92. Following the transaction, the insider now directly owns 161,438 shares in the company, valued at approximately $1,233,386.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Julie B. Feder sold 6,609 shares of Aura Biosciences stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $7.64, for a total transaction of $50,492.76. Following the completion of the transaction, the chief financial officer now owns 62,991 shares in the company, valued at $481,251.24. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

Hedge Funds Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Matrix Capital Management Company LP grew its position in Aura Biosciences by 29.1% in the 4th quarter. Matrix Capital Management Company LP now owns 6,922,870 shares of the company’s stock valued at $61,337,000 after buying an additional 1,560,000 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in Aura Biosciences by 91.8% in the fourth quarter. Eventide Asset Management LLC now owns 5,802,682 shares of the company’s stock valued at $51,412,000 after acquiring an additional 2,777,777 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in Aura Biosciences by 6.1% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,875,000 shares of the company’s stock valued at $25,789,000 after acquiring an additional 165,000 shares during the period. BlackRock Inc. lifted its holdings in Aura Biosciences by 40.6% in the second quarter. BlackRock Inc. now owns 1,872,132 shares of the company’s stock valued at $23,121,000 after acquiring an additional 541,032 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Aura Biosciences by 67.8% in the fourth quarter. Vanguard Group Inc. now owns 1,730,431 shares of the company’s stock valued at $15,332,000 after acquiring an additional 699,337 shares during the period. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.